What is dual-target CD19/CD22 CAR-T therapy, and how is it different from standard CAR-T?

Standard CAR-T therapy typically targets a single antigen, usually CD19. Dual-target CAR-T targets both CD19 and CD22 simultaneously, reducing the risk that tumor cells escape treatment by losing or downregulating one antigen, which can improve remission rates in heterogeneous cancers like DLBCL.

How can international patients access dual-target CAR-T therapy for large B-cell lymphoma in China?

Access typically begins with a case review, where medical records and diagnostic imaging are submitted for evaluation. ChinaCureLink coordinates this process, including urgent arrival logistics for critically ill patients, and helps match patients with hospitals experienced in advanced CAR-T protocols.

What does the treatment and recovery timeline look like for CAR-T therapy?

Timelines vary by case, but this patient showed significant improvement on imaging within 28 days and was well enough to be discharged within two months. Recovery depends on disease severity, treatment response, and individual health factors.

top of page

ChinaCurelink
a MedeboundHEALTH Company

FREE CONSULTATION

28 Days: How Dual-Target CAR-T Turned Around a Critical Lymphoma Case for an Egyptian Patient in China

ChinaCureLink

Tue Sep 01 2026

5 min read

Widget Didn’t Load

Check your internet and refresh this page.

If that doesn’t work, contact us.

bottom of page